These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6148573)

  • 1. Reduction in prostacyclin platelet receptors in active spontaneous angina.
    Neri Serneri GG; Modesti PA; Fortini A; Abbate R; Lombardi A; Gensini GF
    Lancet; 1984 Oct; 2(8407):838-41. PubMed ID: 6148573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human prostacyclin platelet receptors and platelet lipid composition.
    Modesti PA; Abbate R; Prisco D; Gensini GF
    J Lipid Mediat; 1990; 2(6):309-15. PubMed ID: 2133274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
    Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age related changes of platelet prostacyclin receptors in humans.
    Modesti PA; Fortini A; Abbate R; Gensini GF
    Eur J Clin Invest; 1985 Aug; 15(4):204-8. PubMed ID: 2995049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptors for PGI2 and PGD2 on human platelets.
    Siegl AM
    Methods Enzymol; 1982; 86():179-92. PubMed ID: 6290840
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet prostacyclin binding in coronary artery disease.
    Jaschonek K; Karsch KR; Weisenberger H; Tidow S; Faul C; Renn W
    J Am Coll Cardiol; 1986 Aug; 8(2):259-66. PubMed ID: 3016061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris.
    Davì G; Cannizzaro S; Giubilato A; Novo S; Mattina A; Strano A
    Z Kardiol; 1986; 75 Suppl 3():80-2. PubMed ID: 3541421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubilization of prostacyclin membrane receptors from human platelets.
    Tsai AL; Hsu MJ; Vijjeswarapu H; Wu KK
    J Biol Chem; 1989 Jan; 264(1):61-7. PubMed ID: 2642482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human prostacyclin platelet receptors in diabetes mellitus.
    Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
    Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
    Kajikawa N; Nogimori K; Murata T; Nishio S; Uchiyama S
    Arzneimittelforschung; 1989 Apr; 39(4):495-9. PubMed ID: 2665758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise decreases the platelet sensitivity to prostacyclin in patients with angina pectoris.
    Kristensen SD; Schmidt EB; Andersen HR; Dyerberg J
    Prostaglandins Leukot Med; 1985 Oct; 20(1):45-54. PubMed ID: 3906669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
    Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
    Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin I2 receptors in a particulate fraction of platelets of various species.
    Schillinger E; Prior G
    Biochem Pharmacol; 1980 Sep; 29(17):2297-9. PubMed ID: 6252899
    [No Abstract]   [Full Text] [Related]  

  • 16. Platelet PGI2 receptor affinity is reduced in pre-eclampsia.
    Klockenbusch W; Hohlfeld T; Wilhelm M; Somville T; Schrör K
    Br J Clin Pharmacol; 1996 Jun; 41(6):616-8. PubMed ID: 8799531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells.
    Hall JM; Strange PG
    Biosci Rep; 1984 Nov; 4(11):941-8. PubMed ID: 6084527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood.
    Tsai AL; Hsu MJ; Patsch W; Wu KK
    Biochim Biophys Acta; 1991 Dec; 1115(2):131-40. PubMed ID: 1764464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of selective [3H]iloprost binding sites on human platelet membranes.
    Steurer G; Jankovic B; Ettl K; Schernthaner G
    Prog Clin Biol Res; 1987; 242():25-34. PubMed ID: 2444987
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
    Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1979 Jul; 210(1):134-40. PubMed ID: 221643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.